Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) - Paepke, Stefan; Huober, Jens; Kümmel, Sherko; Eidtmann, Holger; Untch, Michael; Costa, Serban Dan; Blohmer, Jens-Uwe; Eiermann, Wolfgang; Gerber, Bernd; Hanusch, Claus Alexander; Hilfrich, Jörn; Jackisch, Christian; et al. (The European journal of cancer, 2016)